The onset of hemorrhages when mirtazapine and venlafaxine were added to escitalopram and the dosage-response relation between bleeding and dosages of these drugs suggest a causal link: Because previous treatments with escitalopram, venlafaxine, and mirtazapine, used alone, did not cause hemorrhages, it appears that this drug combination may have caused them. Escitalopram and venlafaxine (by blocking serotonin reuptake) and mirtazapine (by increasing serotonin release) may have increased serotonin to levels not reached with previous treatments, leading to hemorrhage by platelet aggregation. Its unlikely that the patient had a bleeding stomach ulcer, because fresh blood was seen from his nose and rectum; it is also unlikely that omeprazole increased blood levels of these drugs by blocking CYP2C19. Further, irbesartan does not inhibit P450 cytochromes. Escitalopram and mirtazapine have several metabolic pathways, and venlafaxine is metabolized by CYP2D6 (4). Therefore, pharmacokinetic interactions are unlikely to have caused the hemorrhages. Pharmacodynamic interactions leading to high levels of serotonin are a more likely cause. Escitalopram is a potent inhibitor of serotonin reuptake; venlafaxine less potently inhibits serotonin reuptake; and mirtazapine increases serotonin by blocking alpha-2 adrenergic heteroreceptors (5).
For treatment-resistant depression, clinicians should take care when combining several antidepressants that increase serotonin, bearing in mind that this combination may result in hemorrhages. The only argument for lorazepam as the putative agent appears to be that its use coincided with recognition of the QT abnormality. Electrolyte status was not reported. The QT prolongation persisted for 7 days after the discontinuation of lorazepam and all other psychotropic agents and required pacemaker placement. Even with the patient's reported liver dysfunction (extent unknown), the lorazepam should have been cleared long before 7 days, owing to its half-life of 14 hours and lack of active metabolites (2). If lorazepam was responsible, the QT prolongation should have reversed. In addition, the patient was also receiving another benzodiazepine, diazepam. If lorazepam was responsible, it would need to have a unique mechanism of action-one that is distinct from the other benzodiazepines, which is not the case (2).
The more likely cause of this patient's QT prolongation and, hence, her need for a pacemaker was her cardiovascular disease and complete AV block at admission. The patient's liver dysfunction and diazepam prescription may also have potentiated the effects of the prescribed 2 antipsychotics (quetiapine and pipamperone) and tricyclic antidepressant (trimipramine) (2) . The authors cite a study involving 495 psychiatric patients that found antipsychotics and tricy clic antidepressants, but not benzodiazepines, to be associated with QT prolongation (3). It is curious then that the authors would reach the conclusion they did, because it stands in opposition to the literature. Therefore, to suggest that lorazepam-induced QT prolongation in the face of multiple confounding factors, lack of an expected time course, no obvious mechanism of action for the effect, and literature stating otherwise seems curious. Instead, the case should serve as an example of how, in complicated presentations, the coincidental timing of the onset of events can lead to misinterpreted causal associations. Clinicians should not change their practice with respect to lorazepam because of the cited case; this could potentially limit the drug's appropriate use. Recent studies show that a high number of patients with severe cardiac drug reactions have frequent cardiac comorbidity (2). In addition, most receive drug combinations wherein drugs with similar adverse reaction profiles are often coprescribed. We agree with Dr Crockford that the case we presented and discussed is definitely complex with preexisting cardiovascular risks. However, we do not agree that lorazepam is not possibly associated with QT prolongation in that particular case, and we would like to comment on a few of Dr Crockford's points. First, the electrolyte status revealed no abnormal findings, and the liver enzymes were moderately elevated. Second, the relevance of the half-life of lorazepam in relation to the duration of the QT prolongation is uncertain. Various undesired adverse drug reactions, for example skin reactions and blood dyscrasia, appear after single drug doses. Third, while we agree that a unique mechanism of action for lorazepam, distinct from the other benzodiazepines, seems to be unlikely, daily clinical work shows that substances with almost an identical chemical structure cause different side effects. Fourth, as Dr Crockford points out, there are multiple confounding factors; however, this does not preclude the possibility that lorazepam set off the mechanisms of the persisting QT prolongation.
Inspired by our work in the AMSP, we decided to present our provocative conclusions in this complex case. This case shows that, in patients taking drug combinations and having preexisting cardiovascular risks, physicians should be aware of possible unlikely adverse drug reactions. On our way from case reports to quality management of drug treatment, controversial discussions are important to classify severe adverse drug reactions. As well, further research is needed to elucidate the underlying physiological mechanisms. We definitely agree with Dr Crockford that clinicians should not change their practice with regard to lorazepam in general. Lorazepam is an important and useful drug in daily psychiatric clinical work. As with any drug, it can have side effects, some of which may be rare and peculiar. 
Lithium-Associated Anencephaly
Dear Editor: The most common congenital malformation (CMF) associated with lithium is Ebstein's anomaly. Other reported effects on the fetus are poor respiratory effort, cyanosis, rhythm disturbances, nephrogenic diabetes insipidus, thyroid dysfunction, hypoglycemia, hyperbilirubinemia, floppy baby syndrome, and large-for-gestational-age infants (1) . Neural tube defects have not been reported in humans.
Case Report
A woman, aged 21 years, with no medical or psychiatric history developed acute-onset manic illness that was initially treated with haloperidol (dosage unknown) and lasted for 3 weeks. She presented to our services with neuroleptic malignant syndrome and was treated with bromocriptine up to 15 mg daily, lorazepam up to 6 mg daily, and supportive management. She improved without any neurologic sequel and was started on lithium.
She remained euthymic on lithium 900 mg daily for 2 years (her serum levels were monitored regularly). She married during this period and had genetic counselling (wherein she was advised to practise contraception and to stop taking lithium if she planned a pregnancy). However, owing to contraceptive failure, she conceived. The patient and her husband decided to continue the pregnancy, despite repeat counselling. She stopped taking lithium before 8 completed weeks of pregnancy.
An investigation profile (specifically, HIV, Venereal Disease Research Laboratory slide test, TORCH Screen, hepatitis B antigen, hemogram, renal and liver function tests, and blood sugar level) was normal. She started taking folic acid, calcium, and iron supplements at approximately 8 weeks. Ultrasonography at 12 weeks showed a live fetus, aged 9 weeks. Ultrasonography at 20 weeks showed a live fetus, aged 16 weeks, with evidence of a supraorbital cranial bony defect (suggesting anencephaly) along with a
